Mineralys in Radnor Sees Stock Price Explode

Findings from a pair of studies in tough-to-treat hypertension establish Mineralys’ drug as a “derisked, almost-commercial ...
Mineralys Therapeutics (Nasdaq: MLYS) saw its stock rise by over 40% after reporting positive top-line results from two ...
Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...
Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met ...
Mineralys Therapeutics’s oral hypertension therapy, lorundrostat, has met the primary endpoint in two pivotal studies, ...
In a report released yesterday, Tim Anderson from Bank of America Securities maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – ...